Join Growin Stock Community!
Beta
Back to PFE.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
revenue-chart

PFE Revenue

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

The latest data point for Pfizer's (PFE) revenue in Q1'26 shows $14.45B USD, reflecting a modest year-over-year growth of 5.37% compared to the same quarter in the prior year, indicating a stabilization after recent fluctuations. Over the period from Q2'23 to Q1'26, revenue has exhibited an overall upward trend with notable volatility, starting at $12.73B USD and peaking at $17.76B USD in Q4'24 before settling around $14-17B USD in recent quarters. Year-over-year growth transitioned from consistent declines of -41% to -54% in early periods to positive territory, reaching 33.78% in Q3'24, though it has since shown mixed results with occasional dips like -7.82% in Q1'25. This bar chart pattern suggests improving momentum driven by potential product successes, but analysts should monitor for sustained growth amid the observed quarterly swings.